Jeremy Caldwell, Board of Directors
Jeremy Caldwell, Ph.D.
President and Chief Executive Officer, Inception Therapeutics

Jeremy S. Caldwell has served as the President and CEO of Inception Therapeutics since joining the company in 2018. Jeremy is also a Venture Partner with Versant Ventures. He brings significant expertise in the discovery, development and translation of innovative therapies and the creation of novel drug discovery platforms for applications in patients.

Most recently Jeremy was Executive Vice President and Chief Scientific Officer at Ardelyx Inc where he advanced a portfolio of novel anti-fibrotics and cardiorenal therapeutics to the clinic. Prior to that he was an Entrepreneur-in-Residence at Third Rock Ventures focusing on the formation and development of life science companies. Prior to that Jeremy served as Vice President, Head of RNA Therapeutics, Lead Discovery and Protein Sciences for Merck Research Laboratories, and was Executive Director of Molecular and Cellular Biology, Lead Discovery and Genomics at the Genomics Institute of the Novartis Research Foundation (GNF). In these roles, Jeremy was responsible for building and advancing major aspects of the drug discovery and technology infrastructure, significantly contributing to the success of the drug discovery pipeline coming from Merck and GNF across therapeutic areas.

Jeremy has experience starting life science companies having co-founded the biopharmaceutical company Kalypsys Inc. and developing the technological basis for Rigel Inc. based on his Ph.D thesis. He received a B.S. in Molecular and Cellular Biology from the University of California at Berkeley and a Ph.D. in Molecular Pharmacology from Stanford University. Jeremy has published over 60 peer-reviewed articles and is the lead inventor on over 20 issued and pending patent applications.